Tocilizumab in the treatment of rheumatoid arthritis and beyond. - Wikidata - wikimedia - TriplyDB

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

http://www.wikidata.org/entity/Q37682799

about

Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.Active immunization with Tocilizumab mimotopes induces specific immune responses.The pathogenic role of angiogenesis in rheumatoid arthritis.Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile.A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line.Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?Tocilizumab (Anti-IL-6R) Suppressed TNFα Production by Human Monocytes in an In Vitro Model of Anti-HLA Antibody-Induced Antibody-Dependent Cellular Cytotoxicity.Phosphorylation of STAT proteins by recombinant human IL-6 in immortalized human chondrocyte cell lines, T/C28a2 and C28/I2.Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.Treatment strategies for autoimmune encephalitis.Pharmacological Effect of Caulophyllum robustum on Collagen-Induced Arthritis and Regulation of Nitric Oxide, NF-κB, and Proinflammatory Cytokines In Vivo and In Vitro.A Role for Soluble IL-6 Receptor in Osteoarthritis.Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques

P2860

Q28073706-ABE15EBA-346E-4669-ADA5-3B48EE91541E Q28076558-09F002E5-AAE0-4239-A440-2AD109613725 Q28079074-7DA9E5B8-4ABB-412D-8779-67DC8290044E Q30278790-3EF4AB01-1EB3-4BFA-9329-565B030DE53D Q34456715-0310FB20-9E79-482D-B19F-D3A7588F31A4 Q35649177-E93446A5-1606-4A35-A8E3-2D1821B48696 Q36934777-0811E0B2-2752-46B9-9BE0-C06FA6FCFF60 Q37001999-04ECFDC1-AC5E-4F1E-9CA0-874BE12161EE Q37277020-91070DD8-0E89-4CC5-BBC8-15F8B92B7F84 Q38543052-B2A94A54-E8B8-45DC-B2D4-3591928B92F5 Q38804841-59D9AAC9-D3F7-473F-A8FB-B1A72AB31350 Q39042940-226ABF09-77A3-4301-ABB3-FA9BB2538A17 Q41861341-A12390AA-656A-4784-B140-B6B0FC221AEC Q42280537-A9F57320-68AD-44D7-A9C0-9D9DC68937EA Q47191569-F974F389-BBE1-49E3-9D6D-7E8B8FD25F91 Q47861250-9EDA9A97-13E2-4A5D-95DB-44D8CAB8965D Q49213573-82C6F687-404C-4256-B49A-68C1600D68EC Q49884740-113B2A81-ACFA-43DC-B018-953D449784BA Q52404707-4AEF1734-5C6E-46CB-9977-3F4F9A1C17E8 Q56334431-C94AF701-DDD6-49AC-92FD-6572DBD3AC7D

P2860

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

http://www.wikidata.org/entity/Q37682799

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

@en

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

@nl

type

label

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

@en

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

@nl

prefLabel

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

@en

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

@nl

P1433

Q37682799-25B925BE-A580-4471-AE57-864B37E34D29

P1476

Q37682799-47A1F275-ABE2-42B2-9D2A-B922E74444EE

P2093

Q37682799-0B2E5AF2-D4AA-4213-AF38-588ACAC74CD9

Q37682799-379DA7A7-F1D1-4140-BE6D-569F90948398

Q37682799-700B625A-9B1A-422F-86EB-0FD103929E01

Q37682799-71DF5E4D-B0A2-41AA-9F7E-6E5FBEC45434

Q37682799-7DF4FCF8-F967-465E-8F30-D620CAF195CA

Q37682799-8E34A0A8-FA44-4EFA-80EF-5A00151EC15A

Q37682799-9FE6BF6E-0E29-4CAF-8F0D-17796A41107C

Q37682799-ABD24286-F2C6-48F7-BED4-5FBFB57C519D

Q37682799-CAE8ED6B-1699-43FF-8CA0-3520BB39263D

Q37682799-CD502F96-BFD4-43D9-B516-DC817C43AFFE

P275

Q37682799-3EED3705-A7B6-4859-9EEA-C2F5C4070D1A

P2860

Q37682799-0CB378E4-C82F-49CE-9AF0-6746E98CE075

Q37682799-0F162045-0124-4C6E-A4D6-F38029D4A5ED

Q37682799-153A511C-53BA-4974-88FB-20F83ECB4F13

Q37682799-15E66D76-9959-4A07-BC73-71B599BB670B

Q37682799-1FBDFE39-6CF6-4F85-93D5-D969DDAFE812

Q37682799-28B79819-8D18-496F-82C4-18A87B0DBF4D

Q37682799-29DA116E-0B60-4BFD-A16B-63FCD4CC42B7

Q37682799-2A131F83-F440-4B7E-B0B3-EB8855DEE339

Q37682799-2BFD7EDB-AE15-4A9E-93DD-BC918DF95A0B

Q37682799-2D6AC7A2-794E-474C-8C09-38E3F888EA1C

P304

Q37682799-9D28A275-FC20-456E-B58B-E0588855516B

P31

Q37682799-2E56C0B1-0298-460D-82EC-7C5C98B40A70

Q37682799-AC02F687-1A67-4327-9A2F-BF13C9388552

P356

Q37682799-AAD9956E-B94D-42E5-9245-1EE0A12076F5

P407

Q37682799-0D4FEF48-B482-416F-9FEA-AD10621D5058

P478

Q37682799-AAE29222-1051-4179-BE3A-56998C4109C3

P5008

Q37682799-B66FE298-648D-4D0A-87F8-5341DB654936

P577

Q37682799-7FB37C41-D11D-477F-B3E7-9ED08B987C58

P698

Q37682799-D6415CB4-CB1D-4CEF-B402-BD2D1F05D0F9

P921

Q37682799-51775818-7137-42EE-9795-8EB6CB5A9062

Q37682799-6AAC780D-1424-4017-8394-50806B062A9D

Q37682799-788BB63B-8397-407A-9CFF-040EFA7A92AA

Q37682799-839216C4-6485-4D29-B24B-1AEF1D95FF28

Q37682799-AD07A67A-00C3-4A7C-8D5F-DBB0E9912315

Q37682799-EA12335E-E47F-45AB-8F6C-952CD6A608B5

P932

Q37682799-2539E12D-8E28-4DC0-82C5-DBF7B1FDE3B6

P356

P1433

Drug Design, Development and Therapy

P1476

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

@en

P2093

Abdel Naser Shunaigat

http://www.w3.org/2001/XMLSchema#string

Anjali Shetty

http://www.w3.org/2001/XMLSchema#string

David Perkins

http://www.w3.org/2001/XMLSchema#string

Munir Shawagfeh

http://www.w3.org/2001/XMLSchema#string

Nadera J Sweiss

http://www.w3.org/2001/XMLSchema#string

Olga Vila

http://www.w3.org/2001/XMLSchema#string

Peter Korsten

http://www.w3.org/2001/XMLSchema#string

Ray Sawaqed

http://www.w3.org/2001/XMLSchema#string

Rebekah Hanson

http://www.w3.org/2001/XMLSchema#string

Sameer Smadi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.

P304

349-364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S41437

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2014-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24729685

http://www.w3.org/2001/XMLSchema#string

P921

rheumatoid arthritis

cell surface receptor

monoclonal antibody

membrane proteins

P932

3974690

http://www.w3.org/2001/XMLSchema#string